.Pharmacolibrary.Drugs.ATC.A.A10AD05 .Pharmacolibrary.Drugs.ATC.A.A10AD05| name: | InsulinAspart |
| ATC code: | A10AD05 | route: | subcutaneous |
| n-compartments | 1 |
Insulin aspart is a fast-acting human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is approved for use in many countries and is commonly administered by subcutaneous injection immediately before meals.
Pharmacokinetic model parameters reported for healthy adult volunteers following single subcutaneous injection.
Rasmussen, CH, et al., & Colding-Jørgensen, M (2014). Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 62 65–75. DOI:10.1016/j.ejps.2014.05.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24878388
Haahr, H, & Heise, T (2020). Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical pharmacokinetics 59(2) 155–172. DOI:10.1007/s40262-019-00834-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31667789
Liu, H, et al., & Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug design, development and therapy 19 2863–2871. DOI:10.2147/DDDT.S500347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40236299